$DEFI

Hashdex Commodities Trust Q2 2026: Net income $(1.48M), Revenue $0.0004M — 10-Q Summary

Hashdex Commodities Trust filed its Q2 2026 10-Q. For the three months ended June 30, 2026, it reported net income of -$1.478M versus $3.986M a year earlier. Total income was $411 (revenue $0.0004M) versus $322 in Q2 2025. The sponsor changed from Tidal to Hashdex on Jan. 16, 2026, and the fund now holds spot bitcoin and cash.

Original reporting
Published Aug 12, 2026, 9:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 5:44 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Hashdex Commodities Trust Q2 2026: Net income $(1.48M), Revenue $0.0004M — 10-Q Summary — source image
Decision brief

The 30-second read

$DEFIBearishMed
01

Why it matters

Traders can update expectations for profitability and operational structure based on the reported net loss and the move to primarily hold spot bitcoin with reduced fund-level operating costs after the sponsor transition.

02

Market read

This is a primary disclosure of Q2 financial performance and a portfolio/fee structure change, which can affect near-term sentiment and longer-run cost/risk modeling for the trust.

03

What to watch

The article does not provide NAV performance, creation/redemption activity details, or bitcoin price sensitivity for the quarter, which are key to translating the 10-Q into expected trading behavior.

Relevance 6/10Novelty 6/10Timing: post-market filing, Aug. 12, 2026 (Q2 10-Q released)

Background

The article summarizes Hashdex Commodities Trust’s Q2 2026 Form 10-Q, including sponsor transition, investment strategy, and Q2 financial results.

Company-level read

Ticker impact

$DEFIBearishMedium confidence
Context

Hashdex Commodities Trust filed its Q2 2026 10-Q showing a net loss of $1.478M and a shift to holding spot bitcoin only.

Expected impact

Near-term sentiment likely negative due to the swing from prior-quarter net income to a net loss, partially offset by the stated fee/expense and sponsor transition details.

Evidence & confidence

The article provides concrete Q2 financial results (net loss vs prior-year net income) and specific business changes (sponsor transition, spot-only bitcoin strategy, standardized 0.25% management fee, sponsor assuming most expenses). These are actionable for positioning in the trust, though the magnitude of price impact depends on market expectations not provided here.

Market effects

Spot-bitcoin-only strategy and sponsor expense assumption may influence how traders model costs and tracking risk for bitcoin commodity trusts.

None specified.

None specified.

Counterpoint

The net loss may be driven by non-operating items (e.g., interest income level and accounting effects), while the spot-only shift and sponsor cost assumption could improve longer-run expense drag.

Key entities

  • Hashdex Commodities Trust

    Bitcoin commodity trust that reported Q2 2026 results in its 10-Q and changed sponsor and investment strategy.

  • Tidal

    Prior sponsor replaced by Hashdex on Jan. 16, 2026, per the filing summary.

Related articles

$IBITMed

Bitcoin ETFs draw $853.5M in five-day inflow streak

U.S. spot Bitcoin ETFs saw five straight net inflow sessions totaling about $853.5 million from Aug. 3 to Aug. 7, reversing the prior week’s $61.5 million net outflows, according to SoSoValue. BlackRock’s IBIT led with about $693 million. Total spot Bitcoin ETF net assets were $79.50B. U.S. spot Ethereum ETFs added about $244.9M over the same period.

$MESOMed

Operating cash spending at Mesoblast fell 86% from a year earlier to US$2.1 million.

Mesoblast reported an 86% drop in operating cash spending to $2.1M. Sales of Ryoncil® grew, and trials for rexlemestrocel-L in chronic pain and cardiovascular diseases advanced. FDA confirmed a BLA filing for rexlemestrocel-L in end-stage heart failure. The company met with FDA to discuss treatment for life-threatening gastrointestinal bleeding. Mesoblast is listed on Nasdaq (MESO) and ASX (MSB).

$CHRSMedAI 8/10

Coherus Oncology Reports 89% Response Rate in Early ESCC Study

Coherus Oncology (NASDAQ:CHRS) reported interim results from an early study of its drug in esophageal squamous cell carcinoma (ESCC), showing a 33.3% clinical benefit rate at a 700 mg dose. The company plans to meet with the FDA to discuss the go-forward dose and potential accelerated approval strategies. Coherus also shared interim findings for head and neck cancer, upper gastrointestinal adenocarcinomas, and colorectal cancer.